TITLE

Chelating drug can cause visual defects

PUB. DATE
March 1996
SOURCE
Ophthalmology Times;3/4/96, Vol. 21 Issue 9, p31
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Discusses that the iron chelating drug desferoxamine can cause ocular toxicity. Development of ocular toxicity; Treatment of ocular toxicity.
ACCESSION #
9603205512

 

Related Articles

  • Desferrioxamine-related ocular toxicity: A case report. Simon, Sumu; Athanasiov, Paul A.; Jain, Rajeev; Raymond, Grant; Gilhotra, Jagjit S. // Indian Journal of Ophthalmology;Jul/Aug2012, Vol. 60 Issue 4, p315 

    A 29-year-old lady receiving repeated blood transfusions for β thalassemia since childhood, presented with rapidly deteriorating symptoms of night blindness and peripheral visual field loss. She was recently commenced on high-dose intravenous desferrioxamine for reducing the systemic iron...

  • Case & Comment. Hovan, Michael J.; Pennachio, Dorothy L. // Patient Care;9/30/2001, Vol. 35 Issue 18, p1 

    Presents a case report on a patient with atrial fibrillation who developed ocular toxicity due to amiodarone medication. Medical history of the patient; Dosage of amiodarone; Discussion on the involment of ocular abnormalities. INSET: Do you have an intersting case to share with your colleagues?.

  • Human ocular effects from self-reported exposures to Roundup[sup ®] herbicides. Acquavella, J.F.; Weber, J.A.; Cullen, M.R.; Cruz, O.A.; Martens, M.A.; Holden, L.R.; Riordan, S.; Thompson, M.; Farmer, D. // Human & Experimental Toxicology;1999, Vol. 18 Issue 8, p479 

    We evaluated ocular effects from reported human exposures to Roundup[sup ®] herbicides based on 1513 calls to an American Association of Poison Control Centers (AAPCC) certified regional poison center during the years 1993 through 1997. The preponderance of reported exposures were judged by...

  • Comparison of Toxicological Profiles of Benzalkonium Chloride and Polyquaternium-1: An Experimental Study. Labbé, Antoine; Pauly, Aude; Liang, Hong; Brignole-Baudouin, Françoise; Martin, Chantal; Warnet, Jean-Michel; Baudouin, Christophe // Journal of Ocular Pharmacology & Therapeutics;Aug2006, Vol. 22 Issue 4, p267 

    Purpose: The aim of this study was to compare, in vivo on a rat model, two different preservatives— benzalkonium chloride (BAC) and polyquaternium-1 (PQ-1)—using new experimental approaches. Methods: Thirty (30) eyes of 15 male Lewis rats were used in this study. Rats were randomly...

  • Nonclinical Pharmacodynamics, Pharmacokinetics, and Safety of BOL-303224-A, a Novel Fluoroquinolone Antimicrobial Agent for Topical Ophthalmic Use. Ward, Keith W.; Lepage, Jean-François; Driot, Jean-Yves // Journal of Ocular Pharmacology & Therapeutics;Jun2007, Vol. 23 Issue 3, p243 

    BOL-303224-A is a novel fluoroquinolone that has never been used systemically and that possesses structural modifications intended to improve its potency compared to other fluoroquinolones. This investigation was conducted to evaluate the nonclinical pharmacokinetics, safety, and...

  • Ocular irritation testing in vitro-II. Garrett, Anne Wolven // DCI;Jan1995, Vol. 156 Issue 1, p10 

    Discusses the testing of ingredients and products for ocular safety. Draize ocular irritation test; Friedenwald system of scoring area and intensity of corneal damage; Establishment of in vitro, three dimensional model for the human corneal epithelium; Model as a relevant in vitro method for...

  • Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs. Chisako Kanamaru; Yuichiro Yamada; Shuji Hayashi; Tomochika Matsushita; Atsushi Suda; Miho Nagayasu; Kazuya Kimura; Shuichi Chiba // Journal of Toxicological Sciences;Feb2014, Vol. 39 Issue 1, p59 

    Heat shock protein 90 (Hsp90) is a constitutively expressed molecular chaperone and plays an important role in the folding of client proteins with key regulatory roles in growth, survival, differentiation and metastasis. Because inhibition of Hsp90 degrades multiple oncogenic client proteins, it...

  • Ocular Changes With Oxaliplatin. O'Dea, Denise; Handy, Catherine M.; Wexler, Ann // Clinical Journal of Oncology Nursing;Apr2006, Vol. 10 Issue 2, p227 

    Ocular toxicity, although uncommon, can occur with many chemotherapeutic agents. Platinum compounds have been documented to produce a variety of ocular side effects, and reports have been made of ocular toxicity with oxaliplatin. This article reports on four patients who experienced ocular...

  • Human ocular thelaziasis: A case report from Karnataka. Prabhakar, S. K.; Vijaykumar, G. S.; Mahesh, B. S.; Shanthamallappa // Indian Journal of Medical Microbiology;Apr2015, Vol. 33 Issue 2, p324 

    A letter to the editor is presented in response to the article "Ocular thelaziasis in a 7-month-old infant" in the previous issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics